Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $10.92 million. The enterprise value is -$5.47 million.
| Market Cap | 10.92M |
| Enterprise Value | -5.47M |
Important Dates
The next estimated earnings date is Friday, August 16, 2024, before market open.
| Earnings Date | Aug 16, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 25.31 million shares outstanding. The number of shares has increased by 0.40% in one year.
| Shares Outstanding | 25.31M |
| Shares Change (YoY) | +0.40% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 48.33 |
| Forward PS | 59.49 |
| PB Ratio | 1.82 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.93, with zero debt.
| Current Ratio | 1.93 |
| Quick Ratio | 1.74 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -145.00% and return on invested capital (ROIC) is -322.08%.
| Return on Equity (ROE) | -145.00% |
| Return on Assets (ROA) | -73.80% |
| Return on Capital (ROIC) | -322.08% |
| Revenue Per Employee | $12,556 |
| Profits Per Employee | -$1.01M |
| Employee Count | 18 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.12% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -61.12% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 0.68 |
| Relative Strength Index (RSI) | 45.54 |
| Average Volume (20 Days) | 117,190 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Traws Pharma had revenue of $226,000 and -$18.16 million in losses. Loss per share was -$0.87.
| Revenue | 226,000 |
| Gross Profit | 226,000 |
| Operating Income | -19.37M |
| Pretax Income | -18.16M |
| Net Income | -18.16M |
| EBITDA | -18.14M |
| EBIT | -18.16M |
| Loss Per Share | -$0.87 |
Balance Sheet
The company has $16.39 million in cash and no debt, giving a net cash position of $16.39 million or $0.65 per share.
| Cash & Cash Equivalents | 16.39M |
| Total Debt | n/a |
| Net Cash | 16.39M |
| Net Cash Per Share | $0.65 |
| Equity (Book Value) | 6.02M |
| Book Value Per Share | 0.24 |
| Working Capital | 8.73M |
Cash Flow
| Operating Cash Flow | -17.81M |
| Capital Expenditures | n/a |
| Free Cash Flow | -17.81M |
| FCF Per Share | -$0.85 |
Margins
Gross margin is 100.00%, with operating and profit margins of -8,572.12% and -8,033.63%.
| Gross Margin | 100.00% |
| Operating Margin | -8,572.12% |
| Pretax Margin | -8,033.63% |
| Profit Margin | -8,033.63% |
| EBITDA Margin | -8,026.11% |
| EBIT Margin | -8,033.63% |
| FCF Margin | -7,881.86% |
Dividends & Yields
Traws Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.40% |
| Shareholder Yield | -0.40% |
| Earnings Yield | -166.23% |
| FCF Yield | -163.09% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Traws Pharma has an Altman Z-Score of -39.74 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -39.74 |
| Piotroski F-Score | 2 |